Top

Published in:

01-10-2017 | Original Article

Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line

Authors: Jia Chen, Shoude Zhang, Yi Lin, Beibei Yang, Jiang Cao

Published in: Pathology & Oncology Research | Issue 4/2017

Abstract

The purpose of this study was to develop a recombinant adenovirus with secretory leukoprotease inhibitor (SLPI) promoter-controlled expression for gene therapy of squamous cell carcinoma (SCC). An artificial microRNA targeting epidermal growth factor receptor (EGFR) was designed, and used to construct a replication-defective recombinant adenovirus with SLPI promoter-controlled expression. The silencing efficiency of this vector (Ad-SLPI-EGFRamiR) was detected in Hep-2 cells. Western blotting showed that the expression of 170 kD EGFR was significantly reduced in Hep-2 cells 72 h after infection with Ad-SLPI-EGFRamiR. At a multiplicity of infection (MOI) of 200 pfu/cell, proliferation of Hep-2 cells was highly inhibited by Ad-SLPI-EGFRamiR (inhibition rate: ~70%). The apoptosis rate of Hep-2 cells at 72 h after infection with Ad-SLPI-EGFRamiR at a MOI 35 pfu/cell was 32.8%. The adenovirus constructed was able to specifically inhibit the growth of SCC cells in vitro.

Alam M, Ratner D (2001) Cutaneous squamous-cell carcinoma. N Engl J Med 344:975–983CrossRefPubMed

Yan W, Wistuba II, Emmert-Buck MR, Erickson HS (2011) Squamous cell carcinoma – similarities and differences among anatomical sites. Am J Cancer Res 1:275–300CrossRefPubMed

Pfister DG, Ang KK, Brizel DM et al (2011) Head and neck cancers. J Natl Compr Cancer Netw 9:596–650CrossRef

Olsen KD (2010) Reexamining the treatment of advanced laryngeal cancer. Head Neck 32:1–7PubMed

Zhang S, Chen J, Jiang H, MA H, Yang B (2012) Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. Eur J Clin Pharmacol 68:561–569CrossRefPubMed

Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMed

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127CrossRefPubMed

Moon C, Chae YK, Lee J (2010) Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood) 235:907–920CrossRef

Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493–507CrossRefPubMedPubMedCentral

10.

Young NR, Liu J, Pierce C et al (2013) Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol 7:359–368CrossRefPubMed

11.

Sharafinski ME, Ferris RL, Ferrone S, Grandis JR (2010) Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32:1412–1421CrossRefPubMedPubMedCentral

12.

Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2–16CrossRefPubMed

13.

Rapisarda A, Melillo G (2012) Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 114:237–267CrossRefPubMed

14.

Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59:21–26CrossRefPubMed

15.

Uribe P, Gonzalez S (2011) Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract 207:337–342CrossRefPubMed

16.

Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277:301–308CrossRefPubMed

17.

Rothenberg SM, Engelman JA, Le S, Riese DJ 2nd, Haber DA, Settleman J (2008) Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A 105:12480–12484CrossRefPubMedPubMedCentral

18.

Wang Z, Rao DD, Senzer N, Nemunaitis J (2011) RNA interference and cancer therapy. Pharm Res 28:2983–2995CrossRefPubMed

19.

Chang K, Elledge SJ, Hannon GJ (2006) Lessons from nature: microRNA-based shRNA libraries. Nat Methods 3:707–714CrossRefPubMed

20.

Rein DT, Breidenbach M, Curiel DT (2006) Current developments in adenovirus- based cancer gene therapy. Future Oncol 2:137–143CrossRefPubMedPubMedCentral

21.

Dorer DE, Nettelbeck DM (2009) Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 61:554–571CrossRefPubMed

22.

Chen J, Yang B, Zhang S et al (2012) Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma. Cancer Gene Ther 19:328–335CrossRefPubMed

23.

Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354CrossRefPubMed

24.

Nukiwa T, Suzuki T, Fukuhara T, Kikuchi T (2008) Secretory leukocyte peptidase inhibitor and lung cancer. Cancer Sci 99:849–855CrossRefPubMed

25.

Maemondo M, Saijo Y, Narumi K et al (2004) Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res 64:4611–4620CrossRefPubMed

26.

Rein DT, Breidenbach M, Kirby TO et al (2005) A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 11:1327–1335PubMed

27.

Khare R, Chen CY, Weaver EA, Barry MA (2011) Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11:241–258CrossRefPubMedPubMedCentral

28.

Thaci B, Ulasov IV, Wainwright DA, Lesniak MS (2011) The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2:113–121CrossRefPubMedPubMedCentral

29.

Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT (1996) Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 14:1574–1578CrossRefPubMed

30.

Mizuguchi H, Hayakawa T (2004) Targeted adenovirus vectors. Hum Gene Ther 15:1034–1044CrossRefPubMed

31.

Wu H, Han T, Belousova N et al (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79:3382–3390CrossRefPubMedPubMedCentral

32.

Wickham TJ, Segal DM, Roelvink PW et al (1996) Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70:6831–6838PubMedPubMedCentral

33.

Xia D, Henry LJ, Gerard RD, Deisenhofer J (1994) Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 a resolution. Structure 2:1259–1270CrossRefPubMed

34.

Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22CrossRefPubMed

35.

Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12:1443–1455CrossRefPubMed

Title: Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line
Authors: Jia Chen
Shoude Zhang
Yi Lin
Beibei Yang
Jiang Cao
Publication date: 01-10-2017
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-016-0160-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.

Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis

Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas

Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?

Combination of Interleukin 1 Polymorphism and Helicobacter pylori Infection: an Increased Risk of Gastric Cancer in Pakistani Population

Marked Differences of Haplotype Tagging SNP Distribution, Linkage, and Haplotype Profile of APOA5 Gene in Roma Population Samples

Keynote webinar | Spotlight on antibody–drug conjugates in cancer